ECOR1 CAPITAL LLC
Q3 2026 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001587114
· CRD 167121
· SEC-registered investment adviser
$2.3B Reported Value Total
ECOR1 CAPITAL, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $3,424,668,843, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
5 funds
· $3.4B gross asset value
Hedge Fund: $3.4B · Venture Capital Fund: $65.4M
Source: Form ADV filed 2026-03-30
Reported value
$2.3B
Quarter over quarter
-6.1%
Holdings
34
Top-10 concentration
83.1%
Filing Structure
Reports holdings for
- NODELMAN OLEG (not a 13F filer in our records) · File #028-16767 · Q4 2014 – Q4 2014
Key People
Form ADV owners & control persons
Sarah Christine Marriott
MEMBER, CCO, COO
Oleg Nmn Nodelman
MANAGER
Scott Eric Perlen
CFO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $2.3B |
| Positions | 34 |
| Change in reported value | +9.5% |
| New positions | 9 |
| Exited positions | 6 |
| Position turnover | 37.5% |
| Top-10 concentration | 83.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
34 | $2.3B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
31 | $2.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $2.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
28 | $2.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
30 | $2.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
36 | $1.7B |
|
Q1 2025 13F
Filed May 15, 2025
|
44 | $1.7B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
55 | $2.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
63 | $2.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
55 | $3.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
57 | $4.0B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
51 | $3.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
49 | $3.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
51 | $4.1B |
|
Q1 2023 13F
Filed May 15, 2023
|
58 | $3.1B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
66 | $3.3B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
75 | $3.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
78 | $2.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
86 | $3.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
75 | $3.1B |
28 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ZYME ZYMEWORKS INC | $608.5M | 27.01% |
| 2 | ANAB ANAPTYSBIO INC | $396.1M | 17.58% |
| 3 | BMY C BRISTOL-MYERS SQUIBB CO | $218.4M | 9.7% |
| 4 | CGON CG ONCOLOGY INC | $132.7M | 5.89% |
| 5 | ETON ETON PHARMACEUTICALS INC | $127.2M | 5.65% |
| 6 | TRAX FIRST TRACKS BIOTHERAPEUTICS | $112.5M | 4.99% |
| 7 | AKTS AKTIS ONCOLOGY INC | $93.9M | 4.17% |
| 8 | CRSP CRISPR THERAPEUTICS AG | $76.9M | 3.41% |
| 9 | ANRO ALTO NEUROSCIENCE INC | $57.0M | 2.53% |
| 10 | LKFT LAKEFRONT BIOTHERAPEUTICS NV | $49.4M | 2.19% |
| 11 | ERAS ERASCA INC | $43.2M | 1.92% |
| 12 | ORIC ORIC PHARMACEUTICALS INC | $40.8M | 1.81% |
| 13 | NGNE NEUROGENE INC | $35.4M | 1.57% |
| 14 | ATTO ATTOVIA THERAPEUTICS INC | $34.7M | 1.54% |
| 15 | FULC FULCRUM THERAPEUTICS INC | $25.2M | 1.12% |
| 16 | ADRX ADARX PHARMACEUTICALS INC | $22.9M | 1.02% |
| 17 | STOK STOKE THERAPEUTICS INC | $21.7M | 0.96% |
| 18 | ZBIO ZENAS BIOPHARMA INC | $21.3M | 0.95% |
| 19 | ETRA ELECTRA THERAPEUTICS INC | $19.1M | 0.85% |
| 20 | ATRA ATARA BIOTHERAPEUTICS INC | $13.2M | 0.59% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.